| Literature DB >> 28656051 |
Eleni Galanis1,2, Marsha Taylor1, Kamila Romanowski1, Olga Bitzikos3, Jennifer Jeyes4, Craig Nowakowski5, Jason Stone6, Michelle Murti2,6, Ana Paccagnella7, Sara Forsting3, Sophie Li1, Linda Hoang2,7.
Abstract
Timely surveillance of enteric diseases is necessary to identify and control cases and outbreaks. Our objective was to evaluate the timeliness of enteric disease surveillance in British Columbia, Canada, compare these results to other settings, and recommend improvements. In 2012 and 2013, information was collected from case report forms and laboratory information systems on 2615 Salmonella, shigatoxin-producing E. coli, Shigella, and Listeria infections. Twelve date variables representing the surveillance process from onset of symptoms to case interview and final laboratory results were collected, and intervals were measured. The median time from onset of symptoms to reporting subtyping results to BC epidemiologists was 26-36 days and from onset of symptoms to case interview was 12-14 days. Our findings were comparable to the international literature except for a longer time (up to 29 day difference) to reporting of PFGE results to epidemiologists in BC. Such a delay may impact our ability to identify and solve outbreaks. Several process and system changes were implemented which should improve the timeliness of enteric disease surveillance.Entities:
Year: 2017 PMID: 28656051 PMCID: PMC5471587 DOI: 10.1155/2017/9854103
Source DB: PubMed Journal: Can J Infect Dis Med Microbiol ISSN: 1712-9532 Impact factor: 2.471
Figure 1Enteric disease surveillance process and time intervals measured, British Columbia. PH: public health, PHL: public health laboratory, PFGE: pulsed-field gel electrophoresis, PT: phage type.
Time intervals between steps in the surveillance of enteric diseases, BC, 2012-13.
| Time interval1 |
| STEC median [IQ] (range) in days |
|
| |
|---|---|---|---|---|---|
| Laboratory surveillance | 1: symptom onset to sample collection | 6 [3–11] (0–163) | 4 [3–8] (0–108) | 7 [4–13] (0–137) | 3 [1–4] (0–13) |
| 2: sample collection to sample receipt at PHL | 5 [3–6] (0–36) | 4 [2–6] (0–46) | 4 [3–5] (0–20) | 3 [2–4] (0–7) | |
| 3: sample receipt at PHL to PHL confirmation (incl. serotype or species) | 3 [2–4] (1–70) | 6 [2–21] (1–173) | 1 [1–3] (1–30) | 6 [3–8] (2–69) | |
| 4: PHL confirmation to start of PFGE run | 6 [3–8] (0–55) | 6 [5–10] (1–83) | 8 [5–12] (0–34) | 6 [5–8] (0–13) | |
| 5: start of PFGE run to report of PFGE result to provincial epidemiologists | 10 [8–22] (1–57) | 8 [5–10] (1–44) | 9 [7–14] (2–49) | NA2 | |
| 6: PHL confirmation to isolate sent for PT | 7 [3–8] (0–27) | NA | NA | NA | |
| 7: isolate sent for PT to receipt of PT result at PHL | 5 [5-6] (2–26) | NA | NA | NA | |
| 8: receipt of PT result at PHL to report of PT result to provincial epidemiologists | 9 [2–22] (0–38) | NA | NA | NA | |
| A1: symptom onset to report of results to provincial epidemiologists | 35 [25–48] (15–179) | 26 [22–34] (13–99) | 36 [27–49] (18–165) | NA2 | |
|
| |||||
| Epidemiological surveillance | 9: sample collection to regional health authority notification | 4 [3–6] (0–18) | 5 [3–7] (0–30) | 4 [3–6] (0–35) | 3 [3-4] (1–8) |
| 10: regional health authority notification to case report entry | 0 [0-0] (0–20) | 0 [0-0] (0–2) | 0 [0-0] (0–3) | 0 [0-0] (0-0) | |
| 11: case report entry to first attempt to contact | 1 [0–2] (0–62) | 0 [0-1] (0–19) | 0 [0-1] (0–31) | 1 [1–5] (0–55) | |
| 12: first attempt to contact to completed interview | 0 [0-1] (0–43) | 0 [0-1] (0–38) | 0 [0-1] (0–29) | 0 [0–3] (0–6) | |
| B1: symptom onset to completed interview | 14 [9–21] (2–168) | 12 [8–18] (3–119) | 14 [10–21] (5–148) | 13 [8–17] (3–61) | |
1Numbers refer to intervals in Figure 1. 2Dates for reporting Listeria PFGE to provincial epidemiologists were not available (not in regular weekly report).
Comparison of time intervals between steps in the surveillance of enteric diseases between BC (2012-13) and other regions1.
| Time interval |
| STEC median in days |
|
| |||||
|---|---|---|---|---|---|---|---|---|---|
| BC | Int'l | BC | Int'l | BC | Int'l | BC | Int'l | ||
| Laboratory surveillance | 1: symptom onset to sample collection | 6 | 4 [ | 4 | 3 [ | 7 | 2 [ | 3 | NA |
| 2: sample collection to sample receipt at PHL | 5 | 6 [ | 4 | 5 [ | 4 | NA | 3 | 6 [ | |
| 3: sample receipt at PHL to PHL confirmation (incl. serotype or species) | 3 | 5 [ | 6 | 5 [ | 1 | NA | 6 | NA | |
| A2: symptom onset to start of PFGE | 21 | 18 [ | 19 | 15 [ | 22 | 21 [ | NA | NA | |
| A3: sample collection to report of PT results to provincial epidemiologists | 28 | 25 [ | NA | NA | NA | NA | NA | NA | |
| A4: sample receipt at PHL to report of PFGE result to provincial epidemiologists | 23 | 5 [ | 17 | 4 [ | 33 | NA | NA | 4 [ | |
|
| |||||||||
| Epidemiological surveillance | 9: sample collection to local/regional health authority notification | 4 | 6 [ | 5 | 4 [ | 4 | 6 [ | 3 | 5 [ |
| B1: symptom onset to completed interview | 14 | 14 [ | 12 | 12 [ | 14 | 14 [ | 13 | NA | |
| B2: symptom onset to local/regional health authority notification | 11 | 9 [ | 10 | 7 [ | 13 | 8 [ | 7 | NA | |
| B3: local/regional health authority notification to first attempt to contact | 1 | 2 [ | 1 | 2 [ | NA | NA | 42 | 2 [ | |
1Number in brackets refer to the associated references. 2Only 8 cases.